Sign in

CIK 0001398733

  • Non-accelerated filer
  • Smaller reporting company

Aquestive Therapeutics, Inc.

Sign in to watch
Ticker
AQST
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
208623253
Phone
+1 908-941-1900
Business address
184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
Former names
MonoSol Rx, Inc.
  1. 4 Open-market buy SVP-Chief Financial Officer bought 5,000 shares at $8.87 ($44,350)
  2. 4 Shares withheld for taxes Chief Innovation/Tech Officer gave up 7,177 shares (to pay taxes)
  3. 4 Shares withheld for taxes CEO and President gave up 7,177 shares (to pay taxes)
  4. 4 Open-market buy Commercial Leader bought 1,445 shares at $10.15 ($14,667)
  5. 4 Open-market buy General Counsel bought 1,000 shares at $10.57 ($10,570)
  6. 4 Open-market buy CEO and President bought 1,000 shares at $9.87 ($9,870)
  7. 4 Open-market buy SVP-HR and Org. Development bought 500 shares at $10.34 ($5,170)
  8. 4 Open-market buy Chief Innovation/Tech Officer bought 1,000 shares at $10.25 ($10,250)
  9. 4 Open-market buy SVP-Chief Financial Officer bought 10,000 shares at $9.80 ($98,000)
  10. 4 Open-market buy CEO and President bought 7,950 shares at an average $10.10 ($80,325)
  11. 4 Open-market buy SVP-Operations/Value Delivery bought 200 shares at $9.98 ($1,996)
  12. 4 Shares withheld for taxes CEO and President gave up 162 shares (to pay taxes)
  13. 4 Shares withheld for taxes Chief Innovation/Tech Officer gave up 162 shares (to pay taxes)
  14. 4 Derivatives Options or other derivatives
  15. 3 Insider Initial Statement of Ownership
  16. 4 Shares withheld for taxes CEO and President gave up 6,510 shares (to pay taxes)
  17. 4 Shares withheld for taxes Chief Innovation/Tech Officer gave up 6,510 shares (to pay taxes)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 15 of 17 · 326 filings